ezetimibe has been researched along with gemfibrozil in 15 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (gemfibrozil) | Trials (gemfibrozil) | Recent Studies (post-2010) (gemfibrozil) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 1,483 | 359 | 297 |
| Protein | Taxonomy | ezetimibe (IC50) | gemfibrozil (IC50) |
|---|---|---|---|
| Cytochrome P450 2C8 | Homo sapiens (human) | 4.1 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 7.0795 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 4.0738 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afonso, A; Burnett, DA; Clader, JW; Davis, HR; Huynh, T; Rosenblum, SB; Yumibe, N | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Galetin, A; Gill, KL; Houston, JB | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Affrime, M; Batra, V; Boutros, T; Kosoglou, T; Maxwell, SE; Pember, L; Reyderman, L; Statkevich, P | 1 |
| Crawford, P; Saseen, J; Tweed, E | 1 |
| Patel, J | 1 |
| Chrysohoou, C; Singh, S | 1 |
| Buckley, DB; Kazmi, F; Ogilvie, BW; Paris, BL; Parkinson, A; Yerino, P | 1 |
| Dunn, FL | 1 |
| Gupta, A; Guyomard, V; Myint, PK; Rehman, HU; Zaman, MJ | 1 |
6 review(s) available for ezetimibe and gemfibrozil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin | 2006 |
Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2006 |
System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes.
Topics: Azetidines; Bupropion; Cytochrome P-450 Enzyme Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; Ezetimibe; Gemfibrozil; Glucuronosyltransferase; Hepatocytes; Humans; Microsomes, Liver; Recombinant Proteins | 2010 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides | 2010 |
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Evidence-Based Practice; Ezetimibe; Fatty Acids, Omega-3; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Patient Selection; Phytosterols; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Treatment Outcome | 2010 |
1 trial(s) available for ezetimibe and gemfibrozil
| Article | Year |
|---|---|
Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.
Topics: Administration, Oral; Adolescent; Adult; Anticholesteremic Agents; Area Under Curve; Azetidines; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Ezetimibe; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged; Reference Values | 2004 |
8 other study(ies) available for ezetimibe and gemfibrozil
| Article | Year |
|---|---|
Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cricetinae; Drug Design; Ezetimibe; Liver; Structure-Activity Relationship | 1998 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
Topics: Adult; Aged; Female; Glucuronides; Glucuronosyltransferase; Humans; In Vitro Techniques; Intestinal Mucosa; Intestines; Kidney; Liver; Male; Metabolic Clearance Rate; Microsomes; Middle Aged; Organ Specificity; Pharmaceutical Preparations; Predictive Value of Tests; Protein Binding; Serum Albumin, Bovine; Substrate Specificity; Young Adult | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
How doubling up drugs saves lives. Why doctors increasingly deploy an array of medications all at once.
Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Gemfibrozil; Humans; Niacin | 2004 |
Clinical inquiries. What are effective medication combinations for dyslipidemia?
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents | 2006 |
Drugs for lipids.
Topics: Animals; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin | 2014 |